About tyrosine kinase inhibitors (TKIs) in prostate cancer: Where do we go from here?

Annals of Oncology

Volumn 21, Issue 1, 2009, Pages 183-184

  Aragon Ching, J B ^a   Dahut, W L ^b  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEDIRANIB; DOCETAXEL; MITOGEN ACTIVATED PROTEIN KINASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; SUNITINIB; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMAGE ENHANCEMENT; LETTER; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION;

EID: 77949318787     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp467     Document Type: Letter

References (13)

1. Dror Michaelson M, Regan MM, Oh WK et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009; 20: 913-920.
2. Steinbild S, Mross K, Frost A et al. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br J Cancer 2007; 97: 1480-1485.
3. Chi KN, Ellard SL, Hotte SJ et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 2008; 19: 746-751.
4. Dahut WL, Scripture C, Posadas E et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008; 14: 209-214.
5. Aragon-Ching JB, Jain L, Gulley JL et al. Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int 2009; 103: 1636-1640.
6. Colloca G, Checcaglini F, Venturino A. About sorafenib in castrationresistant prostate cancer. Ann Oncol 2008; 19: 1812-1813; author reply 1813-1814.
7. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159.
8. Karakunnel JJ, Gulley JL, Arlen PM et al. Phase II trial of cediranib (AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC). J Clin Oncol (Meeting Abstracts) 2008; 26: (Abstr 5136).
9. Kelloff GJ, Choyke P, Coffey DS. Challenges in clinical prostate cancer: role of imaging. AJR Am J Roentgenol 2009; 192: 1455-1470.
10. Rosenberg JE, Weinberg VK, Kelly WK et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007; 110: 556-563.
11. Oh WK, Manola J, Babcic V et al. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 2006; 67: 1235-1240.
12. Ross RW, Beer TM, Jacobus S et al. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 2008; 112: 521-526.
13. Sternberg CN, Petrylak D, Witjes F et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial. J Clin Oncol (Meeting Abstracts) 2007; 25: (Abstr 5019).